Construction of Vascular Tissues with Macro-Porous Nano-Fibrous Scaffolds and Smooth Muscle Cells Enriched from Differentiated Embryonic Stem Cells by Hu, Jiang et al.
Construction of Vascular Tissues with Macro-Porous
Nano-Fibrous Scaffolds and Smooth Muscle Cells
Enriched from Differentiated Embryonic Stem Cells
Jiang Hu
1., Changqing Xie
2., Haiyun Ma
1, Bo Yang
3, Peter X. Ma
1,4,5,6*, Y. Eugene Chen
2*
1Department of Biologic and Materials Sciences, University of Michigan, Ann Arbor, Michigan, United States of America, 2Department of Internal Medicine,
Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, United States of America, 3Department of Cardiac Surgery, Cardiovascular Center, University of
Michigan, Ann Arbor, Michigan, United States of America, 4Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, United States of America,
5Macromolecular Science and Engineering Center, University of Michigan, Ann Arbor, Michigan, United States of America, 6Department of Materials Science and
Engineering, University of Michigan, Ann Arbor, Michigan, United States of America
Abstract
Vascular smooth muscle cells (SMCs) have been broadly used for constructing tissue-engineered blood vessels. However,
the availability of mature SMCs from donors or patients is very limited. Derivation of SMCs by differentiating embryonic
stem cells (ESCs) has been reported, but not widely utilized in vascular tissue engineering due to low induction efficiency
and, hence, low SMC purity. To address these problems, SMCs were enriched from retinoic acid induced mouse ESCs with
LacZ genetic labeling under the control of SM22a promoter as the positive sorting marker in the present study. The sorted
SMCs were characterized and then cultured on three-dimensional macro-porous nano-fibrous scaffolds in vitro or implanted
subcutaneously into nude mice after being seeded on the scaffolds. Our data showed that the LacZ staining, which reflected
the corresponding SMC marker SM22a expression level, was efficient as a positive selection marker to dramatically enrich
SMCs and eliminate other cell types. After the sorted cells were seeded into the three-dimensional nano-fibrous scaffolds,
continuous retinoic acid treatment further enhanced the SMC marker gene expression level while inhibited pluripotent
maker gene expression level during the in vitro culture. Meanwhile, after being implanted subcutaneously into nude mice,
the implanted cells maintained the positive LacZ staining within the constructs and no teratoma formation was observed. In
conclusion, our results demonstrated the potential of SMCs derived from ESCs as a promising cell source for therapeutic
vascular tissue engineering and disease model applications.
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Introduction
Vascular smooth muscle cells (SMCs) constitute the principal
layer of all small and large blood vessels in the body. Functional
deficiency of vascular SMCs plays a central role in the progression
of a large number of major human diseases [1,2]. Many
therapeutic treatments to cardiovascular diseases have either
enhanced in situ blood vessel formation or implanted in vitro
constructed blood vessels. The efforts to construct tissue-
engineered blood vessels in vitro using mature vascular SMCs
isolated from donor vascular tissues have been extensively
reported [3–5]. However, mature vascular SMCs have limited
ability to proliferate and the cell source is very limited. Embryonic
stem cells (ESCs) have shown promise as a therapeutic cell source
because of the capacity of self-renewal and the potential to
differentiate into various cell types in the adult body. A growing
number of studies have demonstrated the differentiation capabil-
ities of ESCs into lineage-specific cells under the appropriate
stimuli and the control of a range of signal pathway complex [6].
We and others have utilized a two-dimensional monolayer culture
system for cardiovascular differentiation [7–9], which has
facilitated the dissection of molecular and cellular mechanisms of
cardiovascular development [10,11]. However, one of the major
challenges for the application of ESC-derived SMCs to the
construction of functional vascular tissues is the heterogeneous cell
population derived from pluripotent stem cells, which may lead to
teratoma formation or inferior tissue organization. Thus strategies
have to be developed to efficiently induce and enrich SMCs before
the cells can be used for vascular tissue engineering. Another
challenge is to develop a suitable porous scaffold to support
vascular tissue development. We recently developed three-
dimensional (3D) macro-porous nano-fibrous (NF) scaffolds and
found them to preferentially support contractile phenotype of
human aorta SMCs under in vitro culture conditions [3], which
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tissues. In this study, SMCs derived from the differentiated mouse
SM22a
2/2LacZ ESCs were enriched by positive cell sorting, and
the 3D NF scaffolds were shown to support the growth of sorted
cells both in vitro and in vivo.
Materials and Methods
SMC differentiation of SM22a
2/2LacZ ESCs
SM22a
2/2LacZ ESCs were kindly provided by Dr. Li Li from
Wayne State University, who published the SM22a-KO mice data
previously [12]. The ESCs were expanded and induced to
differentiate into SMCs in vitro when treated with 10
25 M all
trans-retinoid acid (RA) following the protocol described in our
previous publication [8]. The vehicle dimethyl sulfoxide (DMSO)
treatment served as a spontaneous differentiation control.
b-gal staining
A b-gal staining kit (Invitrogen, Carlsbad, CA) was used for b-
gal staining. The derived cells after treatment with either the
DMSO or RA for different time periods were fixed with 2%
formaldehyde and incubated with an X-gal containing solution,
according to the manufacturer’s instructions. For b-gal staining of
the implants, sections (5 mm thick) were generated using a cryostat
(CM 1850, Leica Microsystems) and thaw-mounted onto glass
slides and stored at 220uC until staining. The cell nuclei were
counterstained with fast red (Vector Lab, Burlingame, CA).
Implant samples were also stained with hematoxylin and eosin
(H&E).
Fluorescence activated cell sorting (FACS)
Cell suspension preparation and FACS were performed
following published methods [13]. Briefly, differentiated cells
cultured on Petri dishes were digested with trypsin and then
centrifuged to remove the supernatant. Cells were re-suspended in
staining medium to a density of ,10
7 cells/mL and loaded with 5-
chloromethylfluorescein di-b-D-galactopyranoside (FDG) by add-
ing 100 mL 2 mM pre-warmed FDG working solution. Cells were
mixed rapidly and incubated in a 37uC water bath for 1 minute.
Then the FDG loading was stopped by adding 1.8 mL ice-cold
staining buffer. The cells were kept on ice prior to FACS. The
background autofluorescence compensation was set with unstained
cells. The cells with fluorescence labeling (LacZ positive) were
analyzed and sorted using the FACSCalibur
TM system (BD
Biosciences, San Jose, CA) following the user’s guide.
Immunofluorescence staining
Sorted cells were replated on 0.1% gelatin-coated chamber
vessels (BD Biosciences) and incubated in the culture medium
overnight. Cells were then fixed, permeabilized and incubated
overnight with smooth muscle-a-actin (a-SMA) antibody at 1:1000
dilutions (Millipore, Temecula, CA). After rinsing, samples were
incubated with Alexa Fluor-488 conjugated secondary antibody
(Molecular Probe, Eugene, OR) for 1 hour. The cell nuclei were
co-stained with 49,6-diamidino-2-phenylindole (DAPI) (Molecular
Probe). Samples were observed under an Olympus BX51
microscope.
Fabrication of 3D macro-porous NF scaffolds
3D macro-porous NF scaffolds were fabricated following our
previous publication [3]. Briefly, 10wt/v% poly(L-lactide) (PLLA)
(Boehringer Ingelheim, Ingelheim, Germany) in tetrahydrofuran
solution was cast into an assembled sugar template from bound
sugar spheres with a diameter of 125–250 mm under a mild
vacuum. After phase separation at 220uC overnight, the polymer-
sugar composite was immersed into cyclohexane to exchange
tetrahydrofuran for 2 days. The resulting polymer-sugar compos-
ites were freeze-dried and the sugar spheres were leached out in
distilled water. The obtained macro-porous NF scaffolds were
freeze-dried again and cut into circular disks with dimensions of
3.6 mm in diameter and 1 mm in thickness. The scaffolds were
sterilized with ethylene oxide before use.
Cell culture on 3D macro-porous NF scaffolds
The sterile 3D NF scaffolds were pre-wetted in 70% ethanol for
30 minutes, washed three times with PBS for 30 minutes each,
and twice in cell culture medium for 2 hours each. 2.5610
5 cells
were seeded on each scaffold. The cell-seeded scaffolds were then
transferred to 6-well plates on an orbital shaker [14]. The medium
was changed twice a week.
Scanning electron microscopy (SEM) observation
Samples were rinsed in PBS, fixed in 2.5% glutaraldehyde and
2% paraformaldehyde overnight, and post-fixed in 1% osmium
tetroxide for 1 hour. Samples were dehydrated in increasing
concentrations of ethanol and hexamethyldisilizane. The samples
were then sputter-coated with gold and observed under a scanning
electron microscope (Philips XL30 FEG).
Gene expression analysis with quantitative real-time PCR
Total cellular RNA and cDNA were prepared with an RNeasy
mini kit (Qiagen, Valencia, CA) and superscript III first-strand
synthesis method (Invitrogen, Carlsbad, CA) following the
manufacturer’s instructions respectively. PCR amplification was
performed with primers selective for individual genes with SYBR
Green supermix kit (Bio-rad, Hercules, CA). PCR primers and
reaction conditions were described previously [11] and in Table
S1. All gene expression level of individual RNA sample was
normalized against 18S RNA as an internal standard.
Histological observation
The cell-scaffold constructs were washed in PBS, fixed with
3.7% formaldehyde, dehydrated in ethanol, and embedded in
paraffin. Sections (5 mm thick) were stained with H&E method.
For immunofluorescence analysis of SMC specific markers, the
slides were de-paraffinized, blocked with serum, incubated with
primary antibodies to a-SMA (1:50 dilution, Millipore) and then
incubated with Alexa Fluor-592 conjugated secondary antibodies
(Invitrogen, Carlsbad, CA). Samples were observed under an
Olympus BX51 microscope.
Subcutaneous implantation
After the sorted SMCs were seeded and cultured on scaffolds for
24 hours, the cell-scaffold constructs were implanted into
subcutaneous pockets on nude mice. Briefly, 6–8 weeks old male
nude mice (Charles River Laboratories, Wilmington, MA) were
anesthetized with isofluorane. Two dorsal midsagittal incisions
were made on the disinfected back. One subcutaneous pocket was
created on each side of each incision using blunt dissection and
one scaffold was implanted into each pocket. Four samples were
implanted randomly for each group (n=4). The mice were
euthanized and the implants were harvested at 2 weeks for b-gal
staining. The animal procedures followed the approved protocol
by the University of Michigan Committee on Use and Care of
Laboratory Animals.
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Numerical data were reported as mean 6 S.D. from triplicate
cell culture (n=3). The Student’s t-test was applied to test the
significance between the groups. The value of p,0.05 was
considered statistically significant.
Results
Enrichment of SMCs from differentiated SM22a
2/2LacZ
ESCs
Under the treatment of RA, the SM22a
2/2LacZ ESCs
monolayer underwent dramatic morphological changes. Through-
out this process, the cells kept proliferating and gradually grew to
confluence. In the meantime, the cells acquired an SMC-like
shape starting from day 2 (Fig. 1A). Gradually, the SMC-like cells
dominated the culture from day 5 and became confluent with a
significant morphological difference compared with the DMSO
treated spontaneous differentiation culture, which showed more
random cellular shapes. The b-gal staining result indicated that
RA treatment induced SM22a
2/2LacZ ESCs to differentiate into
SMCs in a time-dependent manner (Fig. 1B). The number of b-gal
positive cells increased with inducing time. In contrast, only
sporadic staining was observed in spontaneously differentiated
culture. Moreover, b-gal activity was dramatically enhanced in
RA-treated SM22a
2/2LacZ ESCs compared to DMSO-treated
cells at day 8 (data not shown). The differentiated cells were then
sorted. After 6 days of RA induction, the derived SMC population
from SM22a
2/2LacZ ESCs were sorted by FACS with hypotonic
introduction of 5-chloromethylfluorescein di-b-D-galactopyrano-
side (FDG), which is designed to react with intracellular
glutathione and subsequent hydrolysis by b-galactosidase and
generate fluorescent adduct [13]. To eliminate the possibility of
contamination of non-specific cell types with low-level transient
SM22a gene expression, the sorting gate threshold was set to a
value higher than 10
2 fluorescence intensity. As a result, the sorted
cells for further studies accounted for 20–25% of total LacZ
Figure 1. Sorting of SMCs from RA-induced SM22a
2/2LacZ ESCs. (A) Morphology change of SM22a
2/2LacZ ESCs under the treatment of DMSO
(upper panel) or 10
25 M RA (lower panel) respectively as indicated time. (B) Comparison of b-gal staining of cells treated with either DMSO (left
panel) or 10
25 M RA (right panel). The upper panel showed that b-gal staining positive cells accumulated with RA treatment time, while only sporadic
b-gal staining positive cells existed in DMSO-treated cell population. The lower panel showed representative magnified images by day 8. Scale
bar=100 mm. (C–D) Using 5-chloromethylfluorescein di-b-D-galactopyranoside (FDG) to react with intracellular glutathione. In LacZ-positive cells
derived from RA-induced SM22a
2/2LacZ ESCs, the FDG–glutathione adduct was converted to a bright green fluorescent product and LacZ-positive
cells were subsequently sorted through a GFP channel (C) and cultured (D). Left panel: bright field; middle panel: GFP channel; right panel: merge.
Scale bar=100 mm. (E) Immunofluorescence staining of SMCs derived from sorted LacZ-positive cells with SMC-specific marker a-SMA antibody. The
nuclei were co-stained with DAPI. Scale bar=100 mm. (F) Gene expression of sorted cells analyzed by quantitative real-time PCR, compared to
undifferentiated ESCs (control, Ctrl) or cells before sorting. Before: before sorting; After: after sorting. *p,0.05.
doi:10.1371/journal.pone.0035580.g001
Vascular Engineering Using Embryonic Stem Cells
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35580positive cell population (Fig. 1C). Sorted cells displayed typical
SMC-like morphology with a strong fluorescence signal (Fig. 1D)
and strong expression of a-SMA evidenced by immunofluores-
cence staining (Fig. 1E). Gene expression analyses confirmed that
much higher levels of the SMC specific genes, including a-SMA
and SMMHC, were expressed in the purified cell population after
FACS and simultaneously the expression level of both pluripotent
marker (Oct4) and other cell lineage markers, such as endoderm
marker AFP, mesoderm marker GATA2 and ectoderm marker
NeuroD, was dramatically reduced (Fig. 1F). Collectively these
results demonstrated that the above described method can be
used for the enrichment of SMCs from the mixture of
differentiated ESCs and thus allow us to generate purified SMCs
in large quantities for further vascular tissue engineering
applications.
In vitro culture of sorted SMCs on 3D NF scaffolds
Sorted SMCs were then seeded on 3D NF scaffolds (Fig. 2A&B)
and cultured for 2 weeks in the medium containing DMSO or
10
25 M RA. After seeding for 24 hours, the cells aggregated inside
the pores of the scaffolds (Fig. 2C&D). Gene expression analysis
showed enhanced SMC marker gene expressions, including
myocardin (MyoCD), a-SMA and SMMHC, for cells cultured
on 3D NF scaffolds under continuous RA treatment, compared to
DMSO treatment, while the expression of pluoripotent marker
Nanog was kept inhibited by RA treatment (Fig. 3A). H–E staining
showed that the cells distributed throughout the scaffold after 2
weeks of culture for both groups (Fig. 3B). However, immunoflu-
orescence staining showed strong a-SMA positive staining in the
constructs with continuous RA treatment. In contrast, weaker a-
SMA staining was observed in the constructs treated with DMSO
(Fig. 3C).
Subcutaneous implantation of cell-scaffold constructs
After the sorted SMCs were seeded on the scaffold for 24 hours,
the cell-scaffold constructs were subcutaneously implanted into
nude mice. After 2 weeks of implantation, the tissue infiltration
into the scaffolds was observed on all samples. Positive LacZ
staining of implanted cells was observed, while no detectable LacZ
staining was observed in the blank scaffold implants (Fig. 4A),
which indicated the survival of implanted SMCs inside the scaffold
under in vivo conditions and retained the marker gene expression.
Meanwhile, the teroatoma development was not observed on the
cell-scaffold construct implants (Fig. 4B).
Discussion
In this study, we presented a strategy to enrich SMCs from the
differentiated ESCs and use the purified cells to construct vascular
tissues on a macro-porous NF scaffold, which can serve as a
potential platform for engineering therapeutic vascular tissues and
for establishing vascular disease models. Although a number of in
vitro SMC differentiation systems have been established, in which
stem cells were induced to differentiate under the treatment of
cytokines, growth factors or ECM components [8,9,15–19], there
are limited publications showing the application of ESC-derived
SMCs in vascular tissue engineering, largely owing to the
heterogeneous properties of the cells. Given that ESCs have been
considered to be a promising cell source for regenerating various
tissues, we explored the capability of ESC-derived SMCs for
constructing vascular tissues. SM22a is a 22 kDa protein that
physically associates with cytoskeletal apparatus in contractile
SMCs. SM22a-deficient (SM22a
2/2LacZ) mice has been generated
by gene targeting and used to study blood vessel development and
gene function during embryogenesis, wherein, certain initiation
codon of SM22a were replaced by the LacZ reporter [20,21].
Previous study has shown that this replacement does not alter
Figure 2. Representative SEM micrographs of NF scaffold and sorted SMCs seeded on the scaffold. (A–B) Low and high magnification
images of the NF scaffold respectively. The cells were seeded and cultured for 24 hours and observed at low (C) or high (D) magnifications. Arrows
indicate the cell aggregates inside the pores of scaffolds.
doi:10.1371/journal.pone.0035580.g002
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developing mice and SM22a
2/2 mice are viable and fertile [20].
Here, we used the ESCs, which have been employed for the
generation of SM22a
2/2LacZ mice, to generate SMCs in vitro with
LacZ staining as the positive selection marker. Naturally, the
SM22a promoter is highly active in the heart tube and selectively
expressed in a subset of arterial SMCs [20,22–25]. Therefore,
there was a possibility that cardiomyocytes might also be isolated
using the SM22a promoter as the selecting marker. Our previous
study has shown the SMCs, derived from ESCs or induced
Figure 3. In vitro culture of sorted SMCs on 3D NF scaffolds. (A) Gene expression profiles of sorted SMCs before (Ctrl) and after seeded on NF
scaffolds and cultured under the treatment of RA or DMSO for 2 weeks, respectively. (B) Histology of constructs cultured for 2 weeks with H–E
staining. Left panel: DMSO treatment; right panel: RA treatment. (C) Immunofluorescence staining of a-SMA for constructs cultured for 2 weeks.
Upper panel: DMSO treatment; Lower panel: RA treatment. Red: positive a-SMA expression; Blue: nuclei. Scale bar=50 mm. *p,0.05.
doi:10.1371/journal.pone.0035580.g003
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25 M) RA
induction, had very low level of cardiomyocyte specific marker
expression [8], therefore excluding the contamination of
cardiomyocytes in our induction-sorting protocol. The results
demonstrated that SM22a expression and the corresponding
LacZ positive staining within the cell population sorted from
differentiated ESCs exhibited a high degree of SMC specificity,
as evidenced by the high level expression of SMC specific
markers and diminished expression of other cell lineage
markers.
A concern associated with the use of ESCs for therapies is the
retention of undifferentiated pluripotent cells. Studies indicated
that undifferentiated ESCs remained in embryoid bodies even
after 28 days of differentiation and could be eradicated only by
prolonged negative selection [18]. Undifferentiated ESCs are
highly proliferative and have the potential to differentiate into
unwanted cell lineages including teratoma formation, raising a
significant concern over their use for therapeutic applications. The
risk can be reduced if the ESCs are differentiated prior to
transplantation [18,26]. Here, we showed the absence of teratoma
formation in our studies, likely benefited from the high efficiency
of RA induced differentiation protocol and the positive sorting
strategy. However, we observed that after being seeded and
cultured on 3D NF scaffolds, the sorted cells could re-express the
pluripotent genes (i.e., Nanog) when RA was withdrawn early
from the culture medium, indicating that the sorted cells were not
terminally differentiated and longer RA treatment may be
necessary to drive the cells to a mature differentiated phenotype.
Growth factors have also been shown to greatly affect the cell
differentiation [27,28]. The incorporation of a controlled-release
capacity for RA or/and growth factors into the porous NF
scaffolds [29] may further enhance functional vascular tissue
regeneration.
Supporting Information
Table S1 Primers Used for RT-PCR.
(DOC)
Author Contributions
Conceived and designed the experiments: JH CX YEC PXM. Performed
the experiments: JH CX HM. Analyzed the data: JH CX BY. Wrote the
paper: JH CX YEC PXM.
Figure 4. Histology of constructs implanted subcutaneously for 2 weeks. (A) b-gal staining. (Left) blank scaffold implants; (Right) cell-
scaffold construct implants. Blue: positive LacZ staining; Red: nuclei. (B) H&E staining of cell-scaffold construct implants. Scale bar=200 mm.
doi:10.1371/journal.pone.0035580.g004
Vascular Engineering Using Embryonic Stem Cells
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35580References
1. Schwartz SM, deBlois D, O’Brien ER (1995) The intima. Soil for atherosclerosis
and restenosis. Circ Res 77: 445–465.
2. Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular
smooth muscle cell differentiation in development and disease. Physiol Rev 84:
767–801.
3. Hu J, Sun X, Ma H, Xie C, Chen YE, et al. (2010) Porous nanofibrous PLLA
scaffolds for vascular tissue engineering. Biomaterials 31: 7971–7977.
4. Xu ZC, Zhang WJ, Li H, Cui L, Cen L, et al. (2008) Engineering of an elastic
large muscular vessel wall with pulsatile stimulation in bioreactor. Biomaterials
29: 1464–1472.
5. Niklason LE, Abbott W, Gao J, Klagges B, Hirschi KK, et al. (2001)
Morphologic and mechanical characteristics of engineered bovine arteries.
J Vasc Surg 33: 628–638.
6. Pera MF, Tam PP (2010) Extrinsic regulation of pluripotent stem cells. Nature
465: 713–720.
7. Huang H, Zhao X, Chen L, Xu C, Yao X, et al. (2006) Differentiation of human
embryonic stem cells into smooth muscle cells in adherent monolayer culture.
Biochem Biophys Res Commun 351: 321–327.
8. Xie CQ, Huang H, Wei S, Song LS, Zhang J, et al. (2009) A comparison of
murine smooth muscle cells generated from embryonic versus induced
pluripotent stem cells. Stem Cells Dev 18: 741–748.
9. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, et al. (2000) Flk1-
positive cells derived from embryonic stem cells serve as vascular progenitors.
Nature 408: 92–96.
10. Huang H, Xie C, Sun X, Ritchie RP, Zhang J, et al. (2010) miR-10a contributes
to retinoid acid-induced smooth muscle cell differentiation. J Biol Chem 285:
9383–9389.
11. Xie C, Huang H, Sun X, Guo Y, Hamblin M, et al. (2011) MicroRNA-1
regulates smooth muscle cell differentiation by repressing Kruppel-like factor 4.
Stem Cells Dev 20: 205–210.
12. Shen J, Yang M, Ju D, Jiang H, Zheng JP, et al. (2010) Disruption of SM22
promotes inflammation after artery injury via nuclear factor kappaB activation.
Circ Res 106: 1351–1362.
13. Poot M, Arttamangkul S (1997) Verapamil inhibition of enzymatic product
efflux leads to improved detection of beta-galactosidase activity in lacZ-
transfected cells. Cytometry 28: 36–41.
14. Xie C, Hu J, Ma H, Zhang J, Chang LJ, et al. (2011) Three-dimensional growth
of iPS cell-derived smooth muscle cells on nanofibrous scaffolds. Biomaterials 32:
4369–4375.
15. Chen S, Lechleider RJ (2004) Transforming growth factor-beta-induced
differentiation of smooth muscle from a neural crest stem cell line. Circ Res
94: 1195–1202.
16. Hirschi KK, Rohovsky SA, D’Amore PA (1998) PDGF, TGF-beta, and
heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of
10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141:
805–814.
17. Sinha S, Hoofnagle MH, Kingston PA, McCanna ME, Owens GK (2004)
Transforming growth factor-beta1 signaling contributes to development of
smooth muscle cells from embryonic stem cells. Am J Physiol Cell Physiol 287:
C1560–1568.
18. Sinha S, Wamhoff BR, Hoofnagle MH, Thomas J, Neppl RL, et al. (2006)
Assessment of contractility of purified smooth muscle cells derived from
embryonic stem cells. Stem Cells 24: 1678–1688.
19. Oishi K, Ogawa Y, Gamoh S, Uchida MK (2002) Contractile responses of
smooth muscle cells differentiated from rat neural stem cells. J Physiol 540:
139–152.
20. Zhang JC, Kim S, Helmke BP, Yu WW, Du KL, et al. (2001) Analysis of
SM22alpha-deficient mice reveals unanticipated insights into smooth muscle cell
differentiation and function. Mol Cell Biol 21: 1336–1344.
21. Yang M, Jiang H, Li L (2010) Sm22alpha transcription occurs at the early onset
of the cardiovascular system and the intron 1 is dispensable for its transcription
in smooth muscle cells during mouse development. Int J Physiol Pathophysiol
Pharmacol 2: 12–19.
22. Li L, Miano JM, Mercer B, Olson EN (1996) Expression of the SM22alpha
promoter in transgenic mice provides evidence for distinct transcriptional
regulatory programs in vascular and visceral smooth muscle cells. J Cell Biol
132: 849–859.
23. Kim S, Ip HS, Lu MM, Clendenin C, Parmacek MS (1997) A serum response
factor-dependent transcriptional regulatory program identifies distinct smooth
muscle cell sublineages. Mol Cell Biol 17: 2266–2278.
24. Li L, Miano JM, Cserjesi P, Olson EN (1996) SM22 alpha, a marker of adult
smooth muscle, is expressed in multiple myogenic lineages during embryogen-
esis. Circ Res 78: 188–195.
25. Moessler H, Mericskay M, Li Z, Nagl S, Paulin D, et al. (1996) The SM 22
promoter directs tissue-specific expression in arterial but not in venous or
visceral smooth muscle cells in transgenic mice. Development 122: 2415–2425.
26. Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, et al. (2003)
Neural subtype specification of fertilization and nuclear transfer embryonic stem
cells and application in parkinsonian mice. Nat Biotechnol 21: 1200–1207.
27. Srivastava S, Terjung RL, Yang HT (2003) Basic fibroblast growth factor
increases collateral blood flow in spontaneously hypertensive rats. Am J Physiol
Heart Circ Physiol 285: H1190–1197.
28. Hishikawa K, Nakaki T, Fujii T (1999) Transforming growth factor-beta(1)
induces apoptosis via connective tissue growth factor in human aortic smooth
muscle cells. Eur J Pharmacol 385: 287–290.
29. Wei G, Jin Q, Giannobile WV, Ma PX (2006) Nano-fibrous scaffold for
controlled delivery of recombinant human PDGF-BB. J Control Release 112:
103–110.
Vascular Engineering Using Embryonic Stem Cells
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35580